264 related articles for article (PubMed ID: 25070546)
21. An open-label, randomized, phase II trial evaluating the efficacy and safety of standard of care with or without bevacizumab in platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer patients previously treated with bevacizumab for front-line or platinum-sensitive ovarian cancer: rationale, design, and methods of the Japanese Gynecologic Oncology Group study JGOG3023.
Shoji T; Komiyama S; Kigawa J; Tanabe H; Kato K; Itamochi H; Fujiwara H; Kamiura S; Hamano T; Sugiyama T;
BMC Cancer; 2018 Jul; 18(1):771. PubMed ID: 30064406
[TBL] [Abstract][Full Text] [Related]
22. Phase II study of MLN8237 (alisertib), an investigational Aurora A kinase inhibitor, in patients with platinum-resistant or -refractory epithelial ovarian, fallopian tube, or primary peritoneal carcinoma.
Matulonis UA; Sharma S; Ghamande S; Gordon MS; Del Prete SA; Ray-Coquard I; Kutarska E; Liu H; Fingert H; Zhou X; Danaee H; Schilder RJ
Gynecol Oncol; 2012 Oct; 127(1):63-9. PubMed ID: 22772063
[TBL] [Abstract][Full Text] [Related]
23. Randomised phase II study of docetaxel plus vandetanib versus docetaxel followed by vandetanib in patients with persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma: SWOG S0904.
Coleman RL; Moon J; Sood AK; Hu W; Delmore JE; Bonebrake AJ; Anderson GL; Chambers SK; Markman M
Eur J Cancer; 2014 Jun; 50(9):1638-48. PubMed ID: 24709487
[TBL] [Abstract][Full Text] [Related]
24. Second-line chemotherapy with docetaxel and carboplatin in paclitaxel and platinum-pretreated ovarian, fallopian tube, and peritoneal cancer.
Arimoto T; Nakagawa S; Oda K; Kawana K; Yasugi T; Taketani Y
Med Oncol; 2012 Jun; 29(2):1253-4. PubMed ID: 21380784
[TBL] [Abstract][Full Text] [Related]
25. OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer.
Aghajanian C; Blank SV; Goff BA; Judson PL; Teneriello MG; Husain A; Sovak MA; Yi J; Nycum LR
J Clin Oncol; 2012 Jun; 30(17):2039-45. PubMed ID: 22529265
[TBL] [Abstract][Full Text] [Related]
26. Demcizumab combined with paclitaxel for platinum-resistant ovarian, primary peritoneal, and fallopian tube cancer: The SIERRA open-label phase Ib trial.
Coleman RL; Handley KF; Burger R; Molin GZD; Stagg R; Sood AK; Moore KN
Gynecol Oncol; 2020 May; 157(2):386-391. PubMed ID: 32037195
[TBL] [Abstract][Full Text] [Related]
27. A phase II study of cetuximab/paclitaxel/carboplatin for the initial treatment of advanced-stage ovarian, primary peritoneal, or fallopian tube cancer.
Konner J; Schilder RJ; DeRosa FA; Gerst SR; Tew WP; Sabbatini PJ; Hensley ML; Spriggs DR; Aghajanian CA
Gynecol Oncol; 2008 Aug; 110(2):140-5. PubMed ID: 18554700
[TBL] [Abstract][Full Text] [Related]
28. Usefulness of third-line chemotherapy for women with recurrent ovarian, fallopian tube, and primary peritoneal cancer who receive platinum/taxane regimens as first-line therapy.
Nishio S; Katsumata N; Matsumoto K; Tanabe H; Yonemori K; Kouno T; Shimizu C; Ando M; Kamura T; Kasamatsu T; Fujiwara Y
J Cancer Res Clin Oncol; 2009 Apr; 135(4):551-7. PubMed ID: 18830625
[TBL] [Abstract][Full Text] [Related]
29. Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial.
Oza AM; Cibula D; Benzaquen AO; Poole C; Mathijssen RH; Sonke GS; Colombo N; Špaček J; Vuylsteke P; Hirte H; Mahner S; Plante M; Schmalfeldt B; Mackay H; Rowbottom J; Lowe ES; Dougherty B; Barrett JC; Friedlander M
Lancet Oncol; 2015 Jan; 16(1):87-97. PubMed ID: 25481791
[TBL] [Abstract][Full Text] [Related]
30. Weekly topotecan for recurrent ovarian, fallopian tube and primary peritoneal carcinoma: tolerability and efficacy study--the Israeli experience.
Safra T; Berman T; Yachnin A; Bruchim I; Meirovitz M; Barak F; Atlas I; Levy T; Rosengarten OS
Int J Gynecol Cancer; 2013 Mar; 23(3):475-80. PubMed ID: 23435437
[TBL] [Abstract][Full Text] [Related]
31. Phase I evaluation of lenvatinib and weekly paclitaxel in patients with recurrent endometrial, ovarian, fallopian tube, or primary peritoneal Cancer.
Backes FJ; Wei L; Chen M; Hill K; Dzwigalski K; Poi M; Phelps M; Salani R; Copeland LJ; Fowler JM; Cohn DE; Bixel K; Cosgrove C; Hays J; O'Malley D
Gynecol Oncol; 2021 Sep; 162(3):619-625. PubMed ID: 34272090
[TBL] [Abstract][Full Text] [Related]
32. Low drug resistance to both platinum and taxane chemotherapy on an in vitro drug resistance assay predicts improved survival in patients with advanced epithelial ovarian, fallopian and peritoneal cancer.
Matsuo K; Bond VK; Eno ML; Im DD; Rosenshein NB
Int J Cancer; 2009 Dec; 125(11):2721-7. PubMed ID: 19530239
[TBL] [Abstract][Full Text] [Related]
33. Improved survival trends in platinum-resistant patients with advanced ovarian, fallopian or peritoneal cancer treated with first-line paclitaxel/platinum chemotherapy: the impact of novel agents.
Bamias A; Bamia C; Zagouri F; Kostouros E; Kakoyianni K; Rodolakis A; Vlahos G; Haidopoulos D; Thomakos N; Antsaklis A; Dimopoulos MA
Oncology; 2013; 84(3):158-65. PubMed ID: 23296063
[TBL] [Abstract][Full Text] [Related]
34. Randomised phase II trial of weekly ixabepilone ± biweekly bevacizumab for platinum-resistant or refractory ovarian/fallopian tube/primary peritoneal cancer.
Roque DM; Siegel ER; Buza N; Bellone S; Silasi DA; Huang GS; Andikyan V; Clark M; Azodi M; Schwartz PE; Rao GG; Reader JC; Hui P; Tymon-Rosario JR; Harold J; Mauricio D; Zeybek B; Menderes G; Altwerger G; Ratner E; Santin AD
Br J Cancer; 2022 Jun; 126(12):1695-1703. PubMed ID: 35149854
[TBL] [Abstract][Full Text] [Related]
35. Phase III randomized trial of 12 versus 3 months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response to platinum and paclitaxel-based chemotherapy: a Southwest Oncology Group and Gynecologic Oncology Group trial.
Markman M; Liu PY; Wilczynski S; Monk B; Copeland LJ; Alvarez RD; Jiang C; Alberts D; ;
J Clin Oncol; 2003 Jul; 21(13):2460-5. PubMed ID: 12829663
[TBL] [Abstract][Full Text] [Related]
36. Weekly ixabepilone with or without biweekly bevacizumab in the treatment of recurrent or persistent uterine and ovarian/primary peritoneal/fallopian tube cancers: A retrospective review.
Roque DM; Ratner ES; Silasi DA; Azodi M; Rutherford TJ; Schwartz PE; Nelson WK; Santin AD
Gynecol Oncol; 2015 Jun; 137(3):392-400. PubMed ID: 25792179
[TBL] [Abstract][Full Text] [Related]
37. Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial.
Pignata S; Scambia G; Katsaros D; Gallo C; Pujade-Lauraine E; De Placido S; Bologna A; Weber B; Raspagliesi F; Panici PB; Cormio G; Sorio R; Cavazzini MG; Ferrandina G; Breda E; Murgia V; Sacco C; Cinieri S; Salutari V; Ricci C; Pisano C; Greggi S; Lauria R; Lorusso D; Marchetti C; Selvaggi L; Signoriello S; Piccirillo MC; Di Maio M; Perrone F; ; ; ; ;
Lancet Oncol; 2014 Apr; 15(4):396-405. PubMed ID: 24582486
[TBL] [Abstract][Full Text] [Related]
38. A randomized phase II study of cabozantinib versus weekly paclitaxel in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer: An NRG Oncology/Gynecologic Oncology Group study.
Matulonis UA; Sill MW; Makker V; Mutch DG; Carlson JW; Darus CJ; Mannel RS; Bender DP; Crane EK; Aghajanian C
Gynecol Oncol; 2019 Mar; 152(3):548-553. PubMed ID: 30587441
[TBL] [Abstract][Full Text] [Related]
39. Third-line chemotherapy in platinum- and paclitaxel-resistant ovarian, fallopian tube, and primary peritoneal carcinoma patients.
Tangjitgamol S; See HT; Manusirivithaya S; Levenback CF; Gershenson DM; Kavanagh JJ
Int J Gynecol Cancer; 2004; 14(5):804-14. PubMed ID: 15361188
[TBL] [Abstract][Full Text] [Related]
40. A phase II evaluation of elesclomol sodium and weekly paclitaxel in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube or primary peritoneal cancer: An NRG oncology/gynecologic oncology group study.
Monk BJ; Kauderer JT; Moxley KM; Bonebrake AJ; Dewdney SB; Secord AA; Ueland FR; Johnston CM; Aghajanian C
Gynecol Oncol; 2018 Dec; 151(3):422-427. PubMed ID: 30309721
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
